Drugs / HT-0712
HT-0712
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01215552 | Sep → Nov 2010 | — | Dart NeuroScience, LLC | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02013310 | Dec 2013 → Jan 2015 | cognitive impairment with or without cerebellar ataxia | Dart NeuroScience, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00758446 | Sep → Dec 2008 | seasonal allergic rhinitis | Dart NeuroScience, LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2008-07-22 | Dart NeuroScience, LLC | Results Helicon Study of HT-0712 on Primate Memory Formation Reveals Significant Enhancement dartneuroscience.com ↗
Helicon Therapeutics, Inc. today announced results from a study of memory formation in Macaque monkeys, showing that its drug, HT-0712, enhances long-term memory formation. |
| 2007-06-26 | Dart NeuroScience, LLC | Results Results with PDE4 Inhibitor, IPL455,903, May Merit Further Clinical Evaluation. Data Support Uniqueness of Inflazyme's PDE4 Inhibitors dartneuroscience.com ↗
Based on this review, Inflazyme believes that the data may support further clinical studies with IPL455,903, as well as the development of Inflazyme’s other PDE4 inhibitors. |
| 2005-11-23 | Dart NeuroScience, LLC | Results Inflazyme Pharmaceuticals Announces Results from Helicon's Phase Ib Multi-Dose Study with PDE4 Inhibitor; IPL455,903 Reported to be Save and Well Tolerated dartneuroscience.com ↗
Helicon has reported the data indicates that IPL455,903 (also known as HT-0712) was safe and well tolerated in all volunteers and at all doses tested. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2008-07-22 | Dart NeuroScience, LLC | Helicon Study of HT-0712 on Primate Memory Formation Reveals Significant Enhancement dartneuroscience.com ↗ |
| 2007-06-26 | Dart NeuroScience, LLC | Results with PDE4 Inhibitor, IPL455,903, May Merit Further Clinical Evaluation. Data Support Uniqueness of Inflazyme's PDE4 Inhibitors dartneuroscience.com ↗ |
| 2005-11-23 | Dart NeuroScience, LLC | Inflazyme Pharmaceuticals Announces Results from Helicon's Phase Ib Multi-Dose Study with PDE4 Inhibitor; IPL455,903 Reported to be Save and Well Tolerated dartneuroscience.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HT-0712 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02013310 ↗ |
| Known as | BLX-028914 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00758446 ↗ |
| Known as | IPL-455903 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297287 ↗ |
| Known as | OX-914 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297287 ↗ |
| Action | Inhibit | “a selective phosphodiesterase-4 (PDE4) inhibitor” NCT00758446 ↗ |
| Modality | Small molecule | — CHEMBL4297287 ↗ |
| Route | Oral | “two different oral doses of BLX-028914” NCT00758446 ↗ |